Insamo - About the company
Insamo is a seed company based in Berkeley (United States), founded in 2022 by Timothy Craven and Toby Passioura. It operates as a Developer of membrane-permeable and orally available cyclic peptides. Insamo has raised $12M in funding. The company has 721 active competitors, including 223 funded and 179 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.
Company Details
Developer of membrane-permeable and orally available cyclic peptides. The company utilizes an automated platform incorporating machine learning and experimental data to design, synthesize, and test drugs for a broad range of diseases.
- Website
- www.insamo.com/
- Email ID
- *****@insamo.com
Key Metrics
Founded Year
2022
Location
Berkeley, United States
Stage
Seed
Total Funding
$12M in 1 round
Latest Funding Round
Ranked
262nd among 721 active competitors
Employee Count
18 as on Aug 31, 2026
Legal entities associated with Insamo
Insamo is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
INSAMO INC. CIN: 1969222 , United States, Active | $5M - $25M (As on Mar 20, 2023) | 6 (As on Dec 31, 2024) | - |
Sign up to download Insamo's company profile
Insamo's funding and investors
Insamo has raised a total funding of $12M over 1 round. Its latest funding round was a Seed round on Dec 19, 2023 for $*****. 6 investors participated in its latest round. Insamo has 6 institutional investors.
Here is the list of recent funding rounds of Insamo:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 19, 2023 | 2361302 | Seed | 7079831 | 2460111 | 3853934 | 4196732 |
Access funding benchmarks and valuations. Sign up today!View details of Insamo's funding rounds and investors
Insamo's founders and board of directors
Founder? Claim ProfileHere are the details of Insamo's key team members:
- Timothy Craven: Co-Founder & CEO of Insamo.
- Toby Passioura: Co-Founder of Insamo. Contact Info: 1 email address
View details of Insamo's Founder profiles and Board Members
Insamo's employee count trend
Insamo has 18 employees as of Aug 26. Here is Insamo's employee count trend over the years:
Uncover Insamo's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Insamo's Competitors and alternates
Top competitors of Insamo include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Insamo, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
4th | Alexion 1992, Zurich (Switzerland), Acquired | Developer of therapies for patients with devastating and rare diseases | $133M | 66/100 | |
5th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
6th |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
7th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
8th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 69/100 | |
9th | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 68/100 | |
10th |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
262nd |  Insamo 2022, Berkeley (United States), Seed | Developer of membrane-permeable and orally available cyclic peptides | $12M | 38/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Insamo's competitors? Click here to see the top ones
Insamo's Investments and acquisitions
Insamo has made no investments or acquisitions yet.
Reports related to Insamo
Here is the latest report on Insamo's sector:
News related to Insamo
•
Insamo Launches with $12M Funding from Playground Global, venBio, and MRL Ventures Fund to Develop Best-in-Class Membrane-Permeable Macrocyclic PeptidesBusiness Wire•Feb 21, 2024•Insamo, Playground, VenBio, MRLV and 5 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Insamo
Explore our recently published companies
- Chez Labelle - Unfunded company
- Elite Cupid - Unfunded company
- E-QOS - Guinea based, 2026 founded, Unfunded company
- Roney Palace Condominium - Miami Beach based, Unfunded company
- Novelus - 2015 founded, Unfunded company
- T-note Global - Mexico based, 2024 founded, Unfunded company
